Hospital 17.36 yuan a box of medicine, but the drugstore sold 498 yuan, it is difficult to find! What is the "difference" in the huge price difference of this kind of medicine?

Last week, the official website of the national health and Health Commission published the list of the first batch of recommended generic drugs, a total of 34 drugs The so-called generic drugs are the substitute drugs imitated by the pharmaceutical enterprises that do not own the patent after the patent protection period of the patented drugs has ended According to the statistics of the State Drug Administration, generic drugs account for more than 90% of the world's total and 95% of China's total In order to improve the quality of generic drugs, China launched a consistency evaluation policy in 2016, which requires generic drugs to achieve the same results as the efficacy and safety of the original drugs through evaluation tests At present, 211 drug varieties have passed the consistency evaluation, accounting for 73% of 289 varieties in the basic drug catalog However, recently, CCTV financial reporters found that the drugs that passed the consistency evaluation were difficult to buy in drugstores Drugstores rarely comment on generic drugs What's the reason for low volume and high price? Among the 211 drugs that passed the consistency evaluation, CCTV financial reporters selected the most common drugs to treat diarrhea, hypertension and other symptoms There are 9 enterprises that have passed the consistency evaluation for the two drugs, such as montmorillonite powder and amoxicillin However, CCTV financial reporters visited many pharmacies in Beijing and found that none of them sold the drugs of these enterprises Subsequently, CCTV financial reporters selected cefuroxime ester tablets with the number of enterprises passing the consistency evaluation reaching 4, and visited many drugstores and found that only one drugstore sold the drugs passing the evaluation What's more puzzling to CCTV's financial reporters is that at the beginning of this year, 25 kinds of common drugs purchased by the state's "4 + 7" cities with a volume passing the consistency evaluation are hard to be found Among the 10 pharmacies surveyed by CCTV financial reporters, only entecavir dispersible tablets were seen, and the price was many times higher than the hospital's bid price Person in charge of a drugstore in Beijing: 498 yuan a box, 28 pieces, always at this price CCTV financial reporters learned that in the 4 + 7 urban volume procurement organized by the state health insurance bureau at the end of last year, the bid winning price of the drug dropped by 94.12%, and the price in the hospital was 17.36 yuan per box In other pharmacies in Beijing, CCTV financial reporters also found a similar situation, the same as winning the bid to reduce the price of drugs, but the price of pharmacies has not been reduced In response, the head of the drugstore gave such an explanation Person in charge of a drugstore in Beijing: the purchase channels of the hospital are different from those of the drugstore The hospital has state subsidies, but the drugstore does not It is difficult for enterprise drugstores to negotiate, and the "4 + 7" pilot city centralized procurement without drug evaluation means to carry out cross regional drug volume procurement in four municipalities directly under the central government of Beijing, Shanghai, Tianjin, Chongqing and seven cities such as Shenyang and Dalian, so as to replace the high price original research drugs with the generic drugs passing the consistency evaluation, and exchange the quantity for the price But in the actual implementation process, the price of drugstores is much higher than that of hospitals What's the reason? What does this have to do with the difficulty of buying generic drugs? At the end of last year, two drugs produced by a pharmaceutical company in Chengdu, Sichuan Province won the bid to purchase drugs in 4 + 7 cities in China The prices of drugs in hospitals dropped by 23% and 90% respectively, which greatly increased the sales share in 11 major cities The head of the enterprise told reporters that their drugs belong to prescription drugs Compared with hospitals, the sales of pharmacies account for less than 20% But companies also want to take this opportunity to reduce the price of pharmacies and increase sales But many negotiations with some large pharmacies failed to reach an agreement Zhou Jun, vice president of Chengdu Beite Pharmaceutical Co., Ltd.: if the drugstore can't promise how much it can sell and can't promise the advance payment, in a sense, this price reduction will not be established Due to the inability to obtain a lower purchase price, the retail price of the drugstore will naturally remain high, losing the price advantage in the competition with the hospital, and as time goes by, the drugstore will not be willing to purchase drugs that pass the consistency evaluation, so it is difficult for the patients to buy them in the drugstore However, those generic drugs that fail to pass the consistency evaluation are under the pressure of being disqualified from centralized procurement bidding In addition, by the end of 2021, drugs that have not passed the conformity assessment will face the risk of not being registered In the face of smaller and smaller development space, enterprises will seize this last opportunity, increase the expansion of drugstore channels, and give drugstores lower purchase prices Dong Milin Xinyang, JIUZHOUTONG Pharmaceutical Group: in the market of drugstore layout, many manufacturers come to us and ask us to act as agents for this variety, and arrange channels for him to drugstore to do this At present, we have received more such lists Mr Wang: the purchase price of these enterprises is much lower than before, and our sales price has not changed, so the profit is naturally much higher than other drugs The market effect of the policy is gradually emerging The survival of the fittest in the industry intensifies that pharmacies cannot buy the drugs with bid price reduction Can this problem be solved? Industry insiders said that in the future, with the gradual promotion of the consistency evaluation of generic drugs and the policy of volume based procurement, and the continuous adjustment of the government bidding procurement mode, the competition pattern of the upstream and downstream of the whole industry will change More generic drugs with lower prices will appear in pharmacies Some pharmaceutical companies and pharmacies said that in the future, the scope of the country's purchasing cities with volume will continue to expand, the number of winning drugs will also increase significantly, and more generic drugs with reduced price will enter the hospital In this context, in order to gain market share, drugstores will also reduce the price of generic drugs on sale In addition, experts said that in the future, the competition of cheap and high-quality generic drugs will make many small pharmacies gradually eliminated, and the concentration of pharmacies will further improve At the same time, as the number of drugs is evaluated by consistency, it has been regarded as a sign of the strength of the enterprise The pharmaceutical enterprises will also complete the survival of the fittest under the role of the market, and the enterprises with weak innovation ability will be eliminated Zhang Yongjian, director of Research Center for food and drug industry development and supervision, Chinese Academy of Social Sciences: China's pharmaceutical industry needs to change from high-speed development to high-quality development Consistency evaluation can promote and promote this change to some extent Wang Bo, researcher of the National Research Center for drug policy and economic development of the pharmaceutical industry: in the next five to ten years, there will be 120 large groups in China that can compete with Bayer and Pfizer Whether it is the requirement of consistency evaluation or the policy of "purchasing with quantity", the purpose is to actively promote the R & D, production and sales of generic drugs, so that patients can use cheap and high-quality drugs In this process, pharmaceutical enterprises, medical institutions and pharmacies are facing great adjustments How to find the interest balance point between pharmaceutical companies and drugstores, so that more generic drugs can be put on the shelves of drugstores, rather than showing the situation of being hard to find? I'm afraid relevant enterprises and departments need to think about ways.